Sparking Hope and Halfway There
Neuroendocrine Tumor Research Foundation celebrates the halfway point of Spark Hope campaign. $5.3 million raised to date.
The Neuroendocrine Tumor Research Foundation directs your individual donations to breakthrough scientific research. Since 2005, we have funded $36 million in research projects. The Neuroendocrine Research Foundation is a 501(c)(3) organization, so all donations are fully tax-deductible to the extent allowed by law. We are grateful to you for your generosity.
The Neuroendocrine Tumor Research Foundation directs your individual donations to breakthrough scientific research. Since 2005, we have funded $36 million in research projects. The Neuroendocrine Research Foundation is a 501(c)(3) organization, so all donations are fully tax-deductible to the extent allowed by law. We are grateful to you for your generosity.
Neuroendocrine Tumor Research Foundation celebrates the halfway point of Spark Hope campaign. $5.3 million raised to date.
Neuroendocrine tumor podcast explores neuroendocrine tumors (NETS), featuring world-renowned NET specialists and patients living with neuroendocrine cancer.
NETRF’s Aretha Franklin Fund for Neuroendocrine Cancer Research established with a gift from Women’s Informal Network, Detroit.
Aretha Franklin was a trailblazer. She broke barriers as the first woman welcomed into the Rock and Roll Hall of Fame and as the indisputable
Join Me in the Fight by Katherin Mueller As I write this, I am about eight months into my “new normal” aka living with NETs.
New grant explores precision drug delivery in NETs The American Association of Cancer Researchers (AACR) has awarded a NETRF-funded research grant to a Texas researcher
Coping with the uncertainty of a cancer diagnosis means finding ways to take your mind off cancer, to do what you enjoy most, finding meaning and purpose.
Neuroendocrine cancer patients traveling for pleasure, business, or cancer treatment, may need to consider a few extra details to ensure travel goes smoothly. These travel
NETRF-funded researchers identified a cancer cell type that is associated with non-functional pancreatic neuroendocrine tumor (pNET) recurrence. Alpha-like pNET cell expression of the protein ARX can guide prognosis.
NETRF’s Board of Scientific Advisors and external reviewers will begin reading and ranking the 2019 requests for research funding. Wide Range of Requests for NET